Company profile
Tenaya Therapeutics, Inc.
NASDAQ:TNYABiotechnology: Biological Products (No Diagnostic Substances)
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05836259 | phase1_2 | recruiting | 2023-08-10 | 2027-08-01 | Tenaya Therapeutics | Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM |
| NCT06228924 | phase1 | recruiting | 2024-03-26 | 2026-05-01 | Tenaya Therapeutics | Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVC |
FDA applications (0)
No records yet.